<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02409680</url>
  </required_header>
  <id_info>
    <org_study_id>CP ASPIRIN</org_study_id>
    <nct_id>NCT02409680</nct_id>
  </id_info>
  <brief_title>Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)</brief_title>
  <acronym>ASPIRIN</acronym>
  <official_title>Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NICHD Global Network for Women's and Children's Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jawaharlal Nehru Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NICHD Global Network for Women's and Children's Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Available data suggest that low dose aspirin may be a safe, widely available and inexpensive&#xD;
      intervention that may significantly reduce the risk of preterm birth. However, this&#xD;
      possibility needs to be proven in a properly designed randomized controlled trial (RCT) with&#xD;
      preterm birth as the primary outcome. Such a clinical trial in a racially, ethnically and&#xD;
      geographically diverse population could best be accomplished by the established&#xD;
      infrastructure of the Global Network for Women's and Children's Health Research (GN).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Preterm birth (PTB) remains the leading cause of neonatal mortality and long term&#xD;
      disability throughout the developed and developing world. Though complex in its origins, a&#xD;
      growing body of evidence suggests that first trimester administration of low dose aspirin&#xD;
      (LDA) holds promise to reduce the rate of PTB substantially.&#xD;
&#xD;
      Hypothesis: The investigators' primary hypothesis is that nulliparous women with no more than&#xD;
      two previous first trimester pregnancy losses who are treated with LDA daily beginning&#xD;
      between 6 0/7 weeks and 13 6/7 weeks gestational age (GA) through 36 0/7 weeks GA will reduce&#xD;
      the risk of preterm birth from all causes.&#xD;
&#xD;
      Study Design Type: Prospective randomized, placebo-controlled, double-blinded multicenter&#xD;
      clinical trial (patient level 1:1).&#xD;
&#xD;
      Population: Nulliparous women between the ages of 18 (or local age of majority) and 40 with&#xD;
      no more than two previous first trimester pregnancy losses or any second trimester&#xD;
      spontaneous pregnancy loss, a singleton pregnancy between 6 0/7 weeks and 13 6/7 weeks GA&#xD;
      confirmed by ultrasound, and no contraindications to aspirin. Other medical conditions, such&#xD;
      as sickle-cell anemia, may be considered a contraindication per the judgment of the site&#xD;
      investigator.&#xD;
&#xD;
      Intervention: Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic&#xD;
      acid (ASA)], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks&#xD;
      GA compared to an identical appearing placebo. Compliance and outcomes will be assessed&#xD;
      biweekly.&#xD;
&#xD;
      Outcomes:&#xD;
&#xD;
      The primary outcome is to determine whether daily LDA initiated between 6 0/7 weeks and 13&#xD;
      6/7 weeks and continued to 36 0/7 weeks reduces the risk of preterm birth (birth prior to 37&#xD;
      0/7 weeks of pregnancy) by 20%. This will be determined based on assessed date of delivery in&#xD;
      comparison to the projected estimated date of delivery, independent of whether or not the&#xD;
      preterm delivery is indicated or spontaneous.&#xD;
&#xD;
      Secondary outcomes include:&#xD;
&#xD;
        -  Preeclampsia and eclampsia (hypertensive disorders of pregnancy)&#xD;
&#xD;
        -  Small for gestational age&#xD;
&#xD;
        -  Perinatal mortality&#xD;
&#xD;
      Other secondary outcomes of interest are:&#xD;
&#xD;
      Maternal outcomes:&#xD;
&#xD;
        -  Vaginal bleeding&#xD;
&#xD;
        -  Antepartum hemorrhage&#xD;
&#xD;
        -  Postpartum hemorrhage&#xD;
&#xD;
        -  Maternal mortality&#xD;
&#xD;
        -  Late abortion&#xD;
&#xD;
        -  Change in maternal hemoglobin&#xD;
&#xD;
        -  Preterm, preeclampsia&#xD;
&#xD;
      Fetal outcomes:&#xD;
&#xD;
        -  Preterm birth &lt;34 0/7 weeks of pregnancy&#xD;
&#xD;
        -  Birth weight &lt;2500g and &lt;1500g&#xD;
&#xD;
        -  Fetal loss&#xD;
&#xD;
        -  Spontaneous abortion&#xD;
&#xD;
        -  Stillbirth&#xD;
&#xD;
        -  Medical termination of pregnancy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2016</start_date>
  <completion_date type="Actual">April 11, 2019</completion_date>
  <primary_completion_date type="Actual">April 11, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Preterm Birth</measure>
    <time_frame>At delivery</time_frame>
    <description>The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hypertensive Disorders of Pregnancy</measure>
    <time_frame>Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)</time_frame>
    <description>- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Small for Gestational Age (SGA)</measure>
    <time_frame>At delivery or at Day 42 after delivery</time_frame>
    <description>- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Perinatal Mortality</measure>
    <time_frame>At delivery or at Day 42 after delivery</time_frame>
    <description>- Incidence of Perinatal Mortality</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Maternal Outcome 1 - Incidence of Vaginal Bleeding</measure>
    <time_frame>At delivery or at Day 42 after delivery</time_frame>
    <description>- Vaginal bleeding</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal Outcome 2 - Incidence of Antepartum Hemorrhage</measure>
    <time_frame>At delivery or at Day 42 after delivery</time_frame>
    <description>- Antepartum hemorrhage</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal Outcome 3 - Incidence of Postpartum Hemorrhage</measure>
    <time_frame>At delivery or at Day 42 after delivery</time_frame>
    <description>- Postpartum hemorrhage</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal Outcome 4 - Incidence of Maternal Mortality</measure>
    <time_frame>At delivery or at Day 42 after delivery</time_frame>
    <description>- Incidence of Maternal Mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal Outcome 5 - Incidence of Late Abortion</measure>
    <time_frame>At delivery or at Day 42 after delivery</time_frame>
    <description>- Incidence of Late Abortion</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal Outcome 6 - Change in Maternal Hemoglobin</measure>
    <time_frame>At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.</time_frame>
    <description>Hemoglobin &lt; 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal Outcome 7 - Incidence of Preterm, Preeclampsia</measure>
    <time_frame>At delivery or at Day 42 after delivery</time_frame>
    <description>Early preterm delivery (&lt;34 weeks) and hypertensive disorders (i.e.: preeclampsia)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fetal Outcome 1 - Incidence of Early Preterm Delivery (&lt;34 Weeks)</measure>
    <time_frame>At delivery</time_frame>
    <description>- Early preterm delivery (&lt;34 weeks)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fetal Outcome 2 - Incidence of Actual Birth Weight &lt;2500g</measure>
    <time_frame>At delivery</time_frame>
    <description>- Birth weight &lt;2500g</description>
  </other_outcome>
  <other_outcome>
    <measure>Fetal Outcome 3 - Incidence of Actual Birth Weight &lt;1500g</measure>
    <time_frame>At delivery</time_frame>
    <description>- Birth weight &lt;1500g</description>
  </other_outcome>
  <other_outcome>
    <measure>Fetal Outcome 4 - Incidence of Fetal Loss</measure>
    <time_frame>At delivery</time_frame>
    <description>- Incidence of Fetal Loss</description>
  </other_outcome>
  <other_outcome>
    <measure>Fetal Outcome 5 - Incidence of Spontaneous Abortion</measure>
    <time_frame>At delivery</time_frame>
    <description>- Incidence of Spontaneous Abortion</description>
  </other_outcome>
  <other_outcome>
    <measure>Fetal Outcome 6 - Incidence of All Stillbirth</measure>
    <time_frame>At delivery</time_frame>
    <description>- Incidence of All stillbirth</description>
  </other_outcome>
  <other_outcome>
    <measure>Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy</measure>
    <time_frame>At delivery</time_frame>
    <description>- Incidence of Medical Termination of Pregnancy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11976</enrollment>
  <condition>Premature Birth</condition>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will be randomized equally to receive daily low dose aspirin (LDA) [also known as acetylsalicylic acid (ASA)] of 81 mg beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Women will be randomized equally to receive an identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose aspirin</intervention_name>
    <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA compared to an identical appearing placebo. Compliance and outcomes will be assessed biweekly.</description>
    <arm_group_label>Intervention Arm</arm_group_label>
    <other_name>Acetylsalicylic acid (ASA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Nulliparous women between 18 - 40 years of age. Minors who are ≥ 14 years of age may&#xD;
             be enrolled if permitted by the country's ethical guidelines.&#xD;
&#xD;
          -  No more than two previous first trimester pregnancy losses&#xD;
&#xD;
          -  No medical contraindications to aspirin;&#xD;
&#xD;
          -  Single live intrauterine pregnancy (IUP) between 6 0/7 and 13 6/7 weeks GA&#xD;
             corroborated by an early dating ultrasound and with presence of a heartbeat.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women prescribed daily aspirin for more than 7 days;&#xD;
&#xD;
          -  Multiple gestations;&#xD;
&#xD;
          -  Fetal anomaly by ultrasound (Note most fetal anomalies are not detectable by&#xD;
             ultrasounds done at this early gestation. Subsequent discovery of a fetal anomaly is&#xD;
             not viewed as an exclusion.);&#xD;
&#xD;
          -  Hemoglobin &lt; 7.0 gm/dl at screening;&#xD;
&#xD;
          -  Any other medical conditions that may be considered a contraindication per the&#xD;
             judgment of the site investigator (e.g., Lupus, Type 1 Diabetes, or any other known&#xD;
             significant disease)&#xD;
&#xD;
          -  Blood pressure ≥ 140/90 (Systolic blood pressure ≥ 140 and diastolic ≥ 90 at&#xD;
             screening)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marion Koso-Thomas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina, Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinshasa School of Public Health</name>
      <address>
        <city>Kinshasa</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Nutrition of Central America and Panama (INCAP)</name>
      <address>
        <city>Guatemala City</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLE University's Jawaharlal Nehru Medical College</name>
      <address>
        <city>Belgaum</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lata Medical Research Foundation</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moi University School of Medicine</name>
      <address>
        <city>Eldoret</city>
        <zip>30100</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Aga Khan University</name>
      <address>
        <city>Karachi</city>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Teaching Hospital</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
    <country>Guatemala</country>
    <country>India</country>
    <country>Kenya</country>
    <country>Pakistan</country>
    <country>United States</country>
    <country>Zambia</country>
  </location_countries>
  <removed_countries>
    <country>Congo</country>
  </removed_countries>
  <reference>
    <citation>Abramovici A, Cantu J, Jenkins SM. Tocolytic therapy for acute preterm labor. Obstet Gynecol Clin North Am. 2012 Mar;39(1):77-87. doi: 10.1016/j.ogc.2011.12.003. Epub 2012 Jan 4. Review.</citation>
    <PMID>22370109</PMID>
  </reference>
  <reference>
    <citation>Ananth CV, Joseph KS, Oyelese Y, Demissie K, Vintzileos AM. Trends in preterm birth and perinatal mortality among singletons: United States, 1989 through 2000. Obstet Gynecol. 2005 May;105(5 Pt 1):1084-91.</citation>
    <PMID>15863548</PMID>
  </reference>
  <reference>
    <citation>Anderson RN, Smith BL. Deaths: leading causes for 2001. Natl Vital Stat Rep. 2003 Nov 7;52(9):1-85.</citation>
    <PMID>14626726</PMID>
  </reference>
  <reference>
    <citation>Baschat AA, Güclü S, Kush ML, Gembruch U, Weiner CP, Harman CR. Venous Doppler in the prediction of acid-base status of growth-restricted fetuses with elevated placental blood flow resistance. Am J Obstet Gynecol. 2004 Jul;191(1):277-84.</citation>
    <PMID>15295379</PMID>
  </reference>
  <reference>
    <citation>Beck S, Wojdyla D, Say L, Betran AP, Merialdi M, Requejo JH, Rubens C, Menon R, Van Look PF. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Organ. 2010 Jan;88(1):31-8. doi: 10.2471/BLT.08.062554. Epub 2009 Sep 25. Review.</citation>
    <PMID>20428351</PMID>
  </reference>
  <reference>
    <citation>Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA. 2006 Mar 22;295(12):1420-7.</citation>
    <PMID>16551714</PMID>
  </reference>
  <reference>
    <citation>Bower SJ, Harrington KF, Schuchter K, McGirr C, Campbell S. Prediction of pre-eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. Br J Obstet Gynaecol. 1996 Jul;103(7):625-9.</citation>
    <PMID>8688387</PMID>
  </reference>
  <reference>
    <citation>CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997 Jun 7;349(9066):1641-9.</citation>
    <PMID>9186381</PMID>
  </reference>
  <reference>
    <citation>Chavarría ME, Lara-González L, González-Gleason A, García-Paleta Y, Vital-Reyes VS, Reyes A. Prostacyclin/thromboxane early changes in pregnancies that are complicated by preeclampsia. Am J Obstet Gynecol. 2003 Apr;188(4):986-92.</citation>
    <PMID>12712098</PMID>
  </reference>
  <reference>
    <citation>Chien PF, Arnott N, Gordon A, Owen P, Khan KS. How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. BJOG. 2000 Feb;107(2):196-208. Review.</citation>
    <PMID>10688503</PMID>
  </reference>
  <reference>
    <citation>CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet. 1994 Mar 12;343(8898):619-29.</citation>
    <PMID>7906809</PMID>
  </reference>
  <reference>
    <citation>ACOG committee opinion no. 561: Nonmedically indicated early-term deliveries. Obstet Gynecol. 2013 Apr;121(4):911-915. doi: 10.1097/01.AOG.0000428649.57622.a7.</citation>
    <PMID>23635710</PMID>
  </reference>
  <reference>
    <citation>Coomarasamy A, Braunholtz D, Song F, Taylor R, Khan KS. Individualising use of aspirin to prevent pre-eclampsia: a framework for clinical decision making. BJOG. 2003 Oct;110(10):882-8. Review.</citation>
    <PMID>14550356</PMID>
  </reference>
  <reference>
    <citation>Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan KS. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol. 2003 Jun;101(6):1319-32. Review.</citation>
    <PMID>12798543</PMID>
  </reference>
  <reference>
    <citation>Duley L, Henderson-Smart DJ, Knight M, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2004;(1):CD004659. Review. Update in: Cochrane Database Syst Rev. 2007;(2):CD004659.</citation>
    <PMID>14974075</PMID>
  </reference>
  <reference>
    <citation>Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004659. Review. Update in: Cochrane Database Syst Rev. 2019 Oct 30;2019(10):.</citation>
    <PMID>17443552</PMID>
  </reference>
  <reference>
    <citation>Ebrashy A, Ibrahim M, Marzook A, Yousef D. Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial. Croat Med J. 2005 Oct;46(5):826-31.</citation>
    <PMID>16158479</PMID>
  </reference>
  <reference>
    <citation>Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum. 2001 Jun;44(6):1466-7.</citation>
    <PMID>11407709</PMID>
  </reference>
  <reference>
    <citation>FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ 2nd, Lawson JA, Brash AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983 Mar;71(3):676-88.</citation>
    <PMID>6338043</PMID>
  </reference>
  <reference>
    <citation>Goffinet F, Aboulker D, Paris-Llado J, Bucourt M, Uzan M, Papiernik E, Bréart G. Screening with a uterine Doppler in low risk pregnant women followed by low dose aspirin in women with abnormal results: a multicenter randomised controlled trial. BJOG. 2001 May;108(5):510-8.</citation>
    <PMID>11368138</PMID>
  </reference>
  <reference>
    <citation>Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008 Jan 5;371(9606):75-84. doi: 10.1016/S0140-6736(08)60074-4. Review.</citation>
    <PMID>18177778</PMID>
  </reference>
  <reference>
    <citation>Goldenberg RL, Rouse DJ. Prevention of premature birth. N Engl J Med. 1998 Jul 30;339(5):313-20. Review.</citation>
    <PMID>9682045</PMID>
  </reference>
  <reference>
    <citation>Hamilton BE, Martin JA, Ventura SJ. Births: preliminary data for 2012. Natl Vital Stat Rep. 2013 Sep;62(3):1-20.</citation>
    <PMID>24321416</PMID>
  </reference>
  <reference>
    <citation>Heyborne KD. Preeclampsia prevention: lessons from the low-dose aspirin therapy trials. Am J Obstet Gynecol. 2000 Sep;183(3):523-8. Review.</citation>
    <PMID>10992168</PMID>
  </reference>
  <reference>
    <citation>Kajantie E, Eriksson JG, Osmond C, Thornburg K, Barker DJ. Pre-eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki birth cohort study. Stroke. 2009 Apr;40(4):1176-80. doi: 10.1161/STROKEAHA.108.538025. Epub 2009 Mar 5.</citation>
    <PMID>19265049</PMID>
  </reference>
  <reference>
    <citation>Kim YJ, Lee BE, Park HS, Kang JG, Kim JO, Ha EH. Risk factors for preterm birth in Korea: a multicenter prospective study. Gynecol Obstet Invest. 2005;60(4):206-12. Epub 2005 Jul 26.</citation>
    <PMID>16088197</PMID>
  </reference>
  <reference>
    <citation>Knight M, Duley L, Henderson-Smart DJ, King JF. Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database Syst Rev. 2000;(2):CD000492. Review. Update in: Cochrane Database Syst Rev. 2007;(2):CD000492.</citation>
    <PMID>10796208</PMID>
  </reference>
  <reference>
    <citation>Kozer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol. 2002 Dec;187(6):1623-30.</citation>
    <PMID>12501074</PMID>
  </reference>
  <reference>
    <citation>Landau D, Shelef I, Polacheck H, Marks K, Holcberg G. Perinatal vasoconstrictive renal insufficiency associated with maternal nimesulide use. Am J Perinatol. 1999;16(9):441-4.</citation>
    <PMID>10774758</PMID>
  </reference>
  <reference>
    <citation>Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol. 2006;19(3):617-33. Review.</citation>
    <PMID>16781491</PMID>
  </reference>
  <reference>
    <citation>Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2003 Aug 16;327(7411):368.</citation>
    <PMID>12919986</PMID>
  </reference>
  <reference>
    <citation>Loe SM, Sanchez-Ramos L, Kaunitz AM. Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis. Obstet Gynecol. 2005 Jul;106(1):173-9. Review.</citation>
    <PMID>15994634</PMID>
  </reference>
  <reference>
    <citation>Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Italian study of aspirin in pregnancy. Lancet. 1993 Feb 13;341(8842):396-400.</citation>
    <PMID>8094168</PMID>
  </reference>
  <reference>
    <citation>March of Dimes, Save the Children, WHO. (2012). Born Too Soon: The Global Action Report on Preterm Birth. (M. V. K. CP Howson JE Lawn., Ed.). Geneva: World Health Organization.</citation>
  </reference>
  <reference>
    <citation>Marret S, Marchand L, Kaminski M, Larroque B, Arnaud C, Truffert P, Thirez G, Fresson J, Rozé JC, Ancel PY; EPIPAGE Study Group. Prenatal low-dose aspirin and neurobehavioral outcomes of children born very preterm. Pediatrics. 2010 Jan;125(1):e29-34. doi: 10.1542/peds.2009-0994. Epub 2009 Dec 21.</citation>
    <PMID>20026499</PMID>
  </reference>
  <reference>
    <citation>Mathews, T. J., Menacker, F., &amp; MacDorman, M. F. (2004). Infant mortality statistics from the 2002 period: linked birth/infant death data set. National Vital Statistics Reports : From the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System, 53(10), 1-29. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15622996</citation>
  </reference>
  <reference>
    <citation>McCormick MC, Richardson DK. Premature infants grow up. N Engl J Med. 2002 Jan 17;346(3):197-8.</citation>
    <PMID>11796855</PMID>
  </reference>
  <reference>
    <citation>Morris JM, Fay RA, Ellwood DA, Cook CM, Devonald KJ. A randomized controlled trial of aspirin in patients with abnormal uterine artery blood flow. Obstet Gynecol. 1996 Jan;87(1):74-8.</citation>
    <PMID>8532271</PMID>
  </reference>
  <reference>
    <citation>Newnham JP, Godfrey M, Walters BJ, Phillips J, Evans SF. Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial. Aust N Z J Obstet Gynaecol. 1995 Nov;35(4):370-4.</citation>
    <PMID>8717556</PMID>
  </reference>
  <reference>
    <citation>Nørgård B, Puhó E, Czeizel AE, Skriver MV, Sørensen HT. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol. 2005 Mar;192(3):922-3.</citation>
    <PMID>15746692</PMID>
  </reference>
  <reference>
    <citation>Norton ME, Merrill J, Cooper BA, Kuller JA, Clyman RI. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med. 1993 Nov 25;329(22):1602-7.</citation>
    <PMID>8232428</PMID>
  </reference>
  <reference>
    <citation>Papageorghiou AT, Yu CK, Erasmus IE, Cuckle HS, Nicolaides KH. Assessment of risk for the development of pre-eclampsia by maternal characteristics and uterine artery Doppler. BJOG. 2005 Jun;112(6):703-9.</citation>
    <PMID>15924523</PMID>
  </reference>
  <reference>
    <citation>Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005 Dec 1;353(22):2373-83. Review.</citation>
    <PMID>16319386</PMID>
  </reference>
  <reference>
    <citation>Peruzzi L, Gianoglio B, Porcellini MG, Coppo R. Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-1 selective inhibitor nimesulide as tocolytic. Lancet. 1999 Nov 6;354(9190):1615.</citation>
    <PMID>10560684</PMID>
  </reference>
  <reference>
    <citation>Physicians' health study: aspirin and primary prevention of coronary heart disease. N Engl J Med. 1989 Dec 28;321(26):1825-8.</citation>
    <PMID>2594041</PMID>
  </reference>
  <reference>
    <citation>RE, B., &amp; AS, B. (2006). Preterm Birth: Causes, Consequences, and Prevention. (I. of M. of the Academies, Ed.). Washington, DC: The National Academies Press.</citation>
  </reference>
  <reference>
    <citation>Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005 Mar 31;352(13):1293-304. Epub 2005 Mar 7.</citation>
    <PMID>15753114</PMID>
  </reference>
  <reference>
    <citation>Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 2008 Jan 19;371(9608):261-9. doi: 10.1016/S0140-6736(08)60136-1. Review.</citation>
    <PMID>18207020</PMID>
  </reference>
  <reference>
    <citation>Schisterman EF, Silver RM, Lesher LL, Faraggi D, Wactawski-Wende J, Townsend JM, Lynch AM, Perkins NJ, Mumford SL, Galai N. Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial. Lancet. 2014 Jul 5;384(9937):29-36. doi: 10.1016/S0140-6736(14)60157-4. Epub 2014 Apr 2.</citation>
    <PMID>24702835</PMID>
  </reference>
  <reference>
    <citation>Seamon LG, Cohn DE, Henretta MS, Kim KH, Carlson MJ, Phillips GS, Fowler JM. Minimally invasive comprehensive surgical staging for endometrial cancer: Robotics or laparoscopy? Gynecol Oncol. 2009 Apr;113(1):36-41. doi: 10.1016/j.ygyno.2008.12.005. Epub 2009 Jan 24.</citation>
    <PMID>19168206</PMID>
  </reference>
  <reference>
    <citation>Silver RM, Edwin SS, Trautman MS, Simmons DL, Branch DW, Dudley DJ, Mitchell MD. Bacterial lipopolysaccharide-mediated fetal death. Production of a newly recognized form of inducible cyclooxygenase (COX-2) in murine decidua in response to lipopolysaccharide. J Clin Invest. 1995 Feb;95(2):725-31.</citation>
    <PMID>7860753</PMID>
  </reference>
  <reference>
    <citation>Smith GC. Life-table analysis of the risk of perinatal death at term and post term in singleton pregnancies. Am J Obstet Gynecol. 2001 Feb;184(3):489-96.</citation>
    <PMID>11228508</PMID>
  </reference>
  <reference>
    <citation>Smith GC, Shah I, Pell JP, Crossley JA, Dobbie R. Maternal obesity in early pregnancy and risk of spontaneous and elective preterm deliveries: a retrospective cohort study. Am J Public Health. 2007 Jan;97(1):157-62. Epub 2006 Nov 30.</citation>
    <PMID>17138924</PMID>
  </reference>
  <reference>
    <citation>Souter D, Harding J, McCowan L, O'Donnell C, McLeay E, Baxendale H. Antenatal indomethacin--adverse fetal effects confirmed. Aust N Z J Obstet Gynaecol. 1998 Feb;38(1):11-6.</citation>
    <PMID>9521382</PMID>
  </reference>
  <reference>
    <citation>Subtil D, Goeusse P, Houfflin-Debarge V, Puech F, Lequien P, Breart G, Uzan S, Quandalle F, Delcourt YM, Malek YM; Essai Régional Aspirine Mère-Enfant (ERASME) Collaborative Group. Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 2). BJOG. 2003 May;110(5):485-91.</citation>
    <PMID>12742333</PMID>
  </reference>
  <reference>
    <citation>Vainio M, Kujansuu E, Iso-Mustajärvi M, Mäenpää J. Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG. 2002 Feb;109(2):161-7.</citation>
    <PMID>11888098</PMID>
  </reference>
  <reference>
    <citation>Vainio M, Riutta A, Koivisto AM, Mäenpää J. Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders. Acta Obstet Gynecol Scand. 2004 Dec;83(12):1119-23.</citation>
    <PMID>15548142</PMID>
  </reference>
  <reference>
    <citation>Valero De Bernabé J, Soriano T, Albaladejo R, Juarranz M, Calle ME, Martínez D, Domínguez-Rojas V. Risk factors for low birth weight: a review. Eur J Obstet Gynecol Reprod Biol. 2004 Sep 10;116(1):3-15. Review.</citation>
    <PMID>15294360</PMID>
  </reference>
  <reference>
    <citation>Van Marter LJ, Leviton A, Allred EN, Pagano M, Sullivan KF, Cohen A, Epstein MF. Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. Pediatrics. 1996 May;97(5):658-63.</citation>
    <PMID>8628603</PMID>
  </reference>
  <reference>
    <citation>Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003 Jun 15;110(5-6):255-8. Review.</citation>
    <PMID>14592543</PMID>
  </reference>
  <reference>
    <citation>Vermillion ST, Robinson CJ. Antiprostaglandin drugs. Obstet Gynecol Clin North Am. 2005 Sep;32(3):501-17. Review.</citation>
    <PMID>16125046</PMID>
  </reference>
  <reference>
    <citation>Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol. 2002 Jan 1;155(1):26-31.</citation>
    <PMID>11772781</PMID>
  </reference>
  <reference>
    <citation>Yu Y, Cheng Y, Fan J, Chen XS, Klein-Szanto A, Fitzgerald GA, Funk CD. Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. J Clin Invest. 2005 Apr;115(4):986-95. Epub 2005 Mar 17.</citation>
    <PMID>15776109</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <results_first_submitted>January 8, 2021</results_first_submitted>
  <results_first_submitted_qc>August 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 8, 2021</results_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preterm birth</keyword>
  <keyword>Low dose aspirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 21, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT02409680/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Randomized, multi-country, double-masked, placebo-controlled trial of low-dose aspirin (81 mg daily) initiated between 6 weeks and 0 days of pregnancy, and 13 weeks and 6 days of pregnancy, in nulliparous women with an ultrasound confirming gestational age and a singleton viable pregnancy.</recruitment_details>
      <pre_assignment_details>Participants were randomly assigned (1:1, stratified by site) to receive aspirin or placebo tablets of identical appearance, via a sequence generated centrally by the data coordinating center.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention Arm</title>
          <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Arm</title>
          <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5990"/>
                <participants group_id="P2" count="5986"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="5943"/>
                <participants group_id="P2" count="5936"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Included in mITT Analysis</title>
              <participants_list>
                <participants group_id="P1" count="5787"/>
                <participants group_id="P2" count="5771"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5975"/>
                <participants group_id="P2" count="5956"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Women who were eligible according to the modified intention-to-treat (mITT) criteria and included in the mITT analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Intervention Arm</title>
          <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Arm</title>
          <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5787"/>
            <count group_id="B2" value="5771"/>
            <count group_id="B3" value="11558"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Maternal Age (years)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5787"/>
                    <count group_id="B2" value="5771"/>
                    <count group_id="B3" value="11558"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;20 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2233"/>
                    <measurement group_id="B2" value="2273"/>
                    <measurement group_id="B3" value="4506"/>
                  </measurement_list>
                </category>
                <category>
                  <title>20-29 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3429"/>
                    <measurement group_id="B2" value="3372"/>
                    <measurement group_id="B3" value="6801"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;29 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5787"/>
                    <count group_id="B2" value="5771"/>
                    <count group_id="B3" value="11558"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5787"/>
                    <measurement group_id="B2" value="5771"/>
                    <measurement group_id="B3" value="11558"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maternal Education</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5787"/>
                    <count group_id="B2" value="5771"/>
                    <count group_id="B3" value="11558"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No formal schooling</title>
                  <measurement_list>
                    <measurement group_id="B1" value="830"/>
                    <measurement group_id="B2" value="828"/>
                    <measurement group_id="B3" value="1658"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1-6 years of schooling</title>
                  <measurement_list>
                    <measurement group_id="B1" value="857"/>
                    <measurement group_id="B2" value="856"/>
                    <measurement group_id="B3" value="1713"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7-12 years of scholling</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3470"/>
                    <measurement group_id="B2" value="3454"/>
                    <measurement group_id="B3" value="6924"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 13 years of schooling</title>
                  <measurement_list>
                    <measurement group_id="B1" value="629"/>
                    <measurement group_id="B2" value="632"/>
                    <measurement group_id="B3" value="1261"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of pregnancies</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5787"/>
                    <count group_id="B2" value="5771"/>
                    <count group_id="B3" value="11558"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5274"/>
                    <measurement group_id="B2" value="5226"/>
                    <measurement group_id="B3" value="10500"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="451"/>
                    <measurement group_id="B2" value="469"/>
                    <measurement group_id="B3" value="920"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Projected gestational age at enrollment</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5787"/>
                    <count group_id="B2" value="5771"/>
                    <count group_id="B3" value="11558"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.1" lower_limit="8.6" upper_limit="12.0"/>
                    <measurement group_id="B2" value="10.1" lower_limit="8.6" upper_limit="12.0"/>
                    <measurement group_id="B3" value="10.1" lower_limit="8.6" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maternal Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5787"/>
                    <count group_id="B2" value="5771"/>
                    <count group_id="B3" value="11558"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153.1" spread="6.9"/>
                    <measurement group_id="B2" value="153.1" spread="7.0"/>
                    <measurement group_id="B3" value="153.1" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maternal Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5787"/>
                    <count group_id="B2" value="5771"/>
                    <count group_id="B3" value="11558"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" spread="8.9"/>
                    <measurement group_id="B2" value="49.2" spread="8.7"/>
                    <measurement group_id="B3" value="49.2" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maternal body-mass-index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5787"/>
                    <count group_id="B2" value="5771"/>
                    <count group_id="B3" value="11558"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.0" spread="3.8"/>
                    <measurement group_id="B2" value="21.0" spread="3.6"/>
                    <measurement group_id="B3" value="21.0" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antenatal care visits</title>
          <units>visits</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5787"/>
                    <count group_id="B2" value="5771"/>
                    <count group_id="B3" value="11558"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="B2" value="5" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="B3" value="5" lower_limit="4" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Delivery attendant</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5787"/>
                    <count group_id="B2" value="5771"/>
                    <count group_id="B3" value="11558"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Physician</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2938"/>
                    <measurement group_id="B2" value="2908"/>
                    <measurement group_id="B3" value="5846"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Nurse or midwife</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2240"/>
                    <measurement group_id="B2" value="2239"/>
                    <measurement group_id="B3" value="4479"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Traditional birth attendant</title>
                  <measurement_list>
                    <measurement group_id="B1" value="464"/>
                    <measurement group_id="B2" value="473"/>
                    <measurement group_id="B3" value="937"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Family, self, or other acquaintance</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="289"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Delivery mode</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5787"/>
                    <count group_id="B2" value="5771"/>
                    <count group_id="B3" value="11558"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Vaginal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4257"/>
                    <measurement group_id="B2" value="4324"/>
                    <measurement group_id="B3" value="8581"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Caesarean section</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1523"/>
                    <measurement group_id="B2" value="1440"/>
                    <measurement group_id="B3" value="2963"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Miscarriage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Medical termination of pregnancy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Delivery location</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5787"/>
                    <count group_id="B2" value="5771"/>
                    <count group_id="B3" value="11558"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hospital</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3479"/>
                    <measurement group_id="B2" value="3494"/>
                    <measurement group_id="B3" value="6973"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clinic or health care</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1818"/>
                    <measurement group_id="B2" value="1765"/>
                    <measurement group_id="B3" value="3583"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Home or other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="488"/>
                    <measurement group_id="B2" value="509"/>
                    <measurement group_id="B3" value="997"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Site</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5787"/>
                    <count group_id="B2" value="5771"/>
                    <count group_id="B3" value="11558"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Democratic Republic of the Congo</title>
                  <measurement_list>
                    <measurement group_id="B1" value="655"/>
                    <measurement group_id="B2" value="665"/>
                    <measurement group_id="B3" value="1320"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Guatemala</title>
                  <measurement_list>
                    <measurement group_id="B1" value="836"/>
                    <measurement group_id="B2" value="835"/>
                    <measurement group_id="B3" value="1671"/>
                  </measurement_list>
                </category>
                <category>
                  <title>India (Belagavi)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1327"/>
                    <measurement group_id="B2" value="1323"/>
                    <measurement group_id="B3" value="2650"/>
                  </measurement_list>
                </category>
                <category>
                  <title>India (Nagpur)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1026"/>
                    <measurement group_id="B2" value="1020"/>
                    <measurement group_id="B3" value="2046"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Kenya</title>
                  <measurement_list>
                    <measurement group_id="B1" value="673"/>
                    <measurement group_id="B2" value="655"/>
                    <measurement group_id="B3" value="1328"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pakistan</title>
                  <measurement_list>
                    <measurement group_id="B1" value="771"/>
                    <measurement group_id="B2" value="762"/>
                    <measurement group_id="B3" value="1533"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Zambia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="499"/>
                    <measurement group_id="B2" value="511"/>
                    <measurement group_id="B3" value="1010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Preterm Birth</title>
        <description>The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous.</description>
        <time_frame>At delivery</time_frame>
        <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Preterm Birth</title>
          <description>The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous.</description>
          <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5780"/>
                <count group_id="O2" value="5764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="668"/>
                    <measurement group_id="O2" value="754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is there is no treatment effect on preterm delivery.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>A-priori threshold for statistical significance at 0.05 was specified.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hypertensive Disorders of Pregnancy</title>
        <description>- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy.</description>
        <time_frame>Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)</time_frame>
        <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hypertensive Disorders of Pregnancy</title>
          <description>- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy.</description>
          <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5780"/>
                <count group_id="O2" value="5764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352"/>
                    <measurement group_id="O2" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.299</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Small for Gestational Age (SGA)</title>
        <description>- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard</description>
        <time_frame>At delivery or at Day 42 after delivery</time_frame>
        <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Small for Gestational Age (SGA)</title>
          <description>- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard</description>
          <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5492"/>
                <count group_id="O2" value="5467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1506"/>
                    <measurement group_id="O2" value="1564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.171</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Perinatal Mortality</title>
        <description>- Incidence of Perinatal Mortality</description>
        <time_frame>At delivery or at Day 42 after delivery</time_frame>
        <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Perinatal Mortality</title>
          <description>- Incidence of Perinatal Mortality</description>
          <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5779"/>
                <count group_id="O2" value="5763"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264"/>
                    <measurement group_id="O2" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maternal Outcome 1 - Incidence of Vaginal Bleeding</title>
        <description>- Vaginal bleeding</description>
        <time_frame>At delivery or at Day 42 after delivery</time_frame>
        <population>ITT population; numbers reported reflect available data and therefore do not always reflect the total population defined in the ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Outcome 1 - Incidence of Vaginal Bleeding</title>
          <description>- Vaginal bleeding</description>
          <population>ITT population; numbers reported reflect available data and therefore do not always reflect the total population defined in the ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5933"/>
                <count group_id="O2" value="5940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                    <measurement group_id="O2" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.125</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maternal Outcome 2 - Incidence of Antepartum Hemorrhage</title>
        <description>- Antepartum hemorrhage</description>
        <time_frame>At delivery or at Day 42 after delivery</time_frame>
        <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Outcome 2 - Incidence of Antepartum Hemorrhage</title>
          <description>- Antepartum hemorrhage</description>
          <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5761"/>
                <count group_id="O2" value="5746"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.900</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maternal Outcome 3 - Incidence of Postpartum Hemorrhage</title>
        <description>- Postpartum hemorrhage</description>
        <time_frame>At delivery or at Day 42 after delivery</time_frame>
        <population>Safety population (women receiving at least one dose of drug or placebo); numbers reported reflect available data</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Outcome 3 - Incidence of Postpartum Hemorrhage</title>
          <description>- Postpartum hemorrhage</description>
          <population>Safety population (women receiving at least one dose of drug or placebo); numbers reported reflect available data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5928"/>
                <count group_id="O2" value="5907"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.274</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maternal Outcome 4 - Incidence of Maternal Mortality</title>
        <description>- Incidence of Maternal Mortality</description>
        <time_frame>At delivery or at Day 42 after delivery</time_frame>
        <population>ITT population; numbers reported reflect available data and therefore do not always reflect the total population defined in the ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Outcome 4 - Incidence of Maternal Mortality</title>
          <description>- Incidence of Maternal Mortality</description>
          <population>ITT population; numbers reported reflect available data and therefore do not always reflect the total population defined in the ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5958"/>
                <count group_id="O2" value="5948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.512</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maternal Outcome 5 - Incidence of Late Abortion</title>
        <description>- Incidence of Late Abortion</description>
        <time_frame>At delivery or at Day 42 after delivery</time_frame>
        <population>ITT population; numbers reported reflect available data and therefore do not always reflect the total population defined in the ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Outcome 5 - Incidence of Late Abortion</title>
          <description>- Incidence of Late Abortion</description>
          <population>ITT population; numbers reported reflect available data and therefore do not always reflect the total population defined in the ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5819"/>
                <count group_id="O2" value="5808"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.331</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maternal Outcome 6 - Change in Maternal Hemoglobin</title>
        <description>Hemoglobin &lt; 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation</description>
        <time_frame>At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Outcome 6 - Change in Maternal Hemoglobin</title>
          <description>Hemoglobin &lt; 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5393"/>
                <count group_id="O2" value="5398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290"/>
                    <measurement group_id="O2" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maternal Outcome 7 - Incidence of Preterm, Preeclampsia</title>
        <description>Early preterm delivery (&lt;34 weeks) and hypertensive disorders (i.e.: preeclampsia)</description>
        <time_frame>At delivery or at Day 42 after delivery</time_frame>
        <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Outcome 7 - Incidence of Preterm, Preeclampsia</title>
          <description>Early preterm delivery (&lt;34 weeks) and hypertensive disorders (i.e.: preeclampsia)</description>
          <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5780"/>
                <count group_id="O2" value="5764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Fetal Outcome 1 - Incidence of Early Preterm Delivery (&lt;34 Weeks)</title>
        <description>- Early preterm delivery (&lt;34 weeks)</description>
        <time_frame>At delivery</time_frame>
        <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal Outcome 1 - Incidence of Early Preterm Delivery (&lt;34 Weeks)</title>
          <description>- Early preterm delivery (&lt;34 weeks)</description>
          <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5780"/>
                <count group_id="O2" value="5764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189"/>
                    <measurement group_id="O2" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Fetal Outcome 2 - Incidence of Actual Birth Weight &lt;2500g</title>
        <description>- Birth weight &lt;2500g</description>
        <time_frame>At delivery</time_frame>
        <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal Outcome 2 - Incidence of Actual Birth Weight &lt;2500g</title>
          <description>- Birth weight &lt;2500g</description>
          <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5628"/>
                <count group_id="O2" value="5624"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1078"/>
                    <measurement group_id="O2" value="1153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.073</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Fetal Outcome 3 - Incidence of Actual Birth Weight &lt;1500g</title>
        <description>- Birth weight &lt;1500g</description>
        <time_frame>At delivery</time_frame>
        <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal Outcome 3 - Incidence of Actual Birth Weight &lt;1500g</title>
          <description>- Birth weight &lt;1500g</description>
          <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5628"/>
                <count group_id="O2" value="5624"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.084</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Fetal Outcome 4 - Incidence of Fetal Loss</title>
        <description>- Incidence of Fetal Loss</description>
        <time_frame>At delivery</time_frame>
        <population>ITT population; numbers reported reflect available data and therefore do not always reflect the total population defined in the ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal Outcome 4 - Incidence of Fetal Loss</title>
          <description>- Incidence of Fetal Loss</description>
          <population>ITT population; numbers reported reflect available data and therefore do not always reflect the total population defined in the ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5818"/>
                <count group_id="O2" value="5807"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303"/>
                    <measurement group_id="O2" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Fetal Outcome 5 - Incidence of Spontaneous Abortion</title>
        <description>- Incidence of Spontaneous Abortion</description>
        <time_frame>At delivery</time_frame>
        <population>ITT population; numbers reported reflect available data and therefore do not always reflect the total population defined in the ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal Outcome 5 - Incidence of Spontaneous Abortion</title>
          <description>- Incidence of Spontaneous Abortion</description>
          <population>ITT population; numbers reported reflect available data and therefore do not always reflect the total population defined in the ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5956"/>
                <count group_id="O2" value="5946"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.261</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Fetal Outcome 6 - Incidence of All Stillbirth</title>
        <description>- Incidence of All stillbirth</description>
        <time_frame>At delivery</time_frame>
        <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal Outcome 6 - Incidence of All Stillbirth</title>
          <description>- Incidence of All stillbirth</description>
          <population>Modified ITT; numbers reported reflect available data and therefore do not always reflect the total population defined in the mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5780"/>
                <count group_id="O2" value="5764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.141</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy</title>
        <description>- Incidence of Medical Termination of Pregnancy</description>
        <time_frame>At delivery</time_frame>
        <population>ITT population; numbers reported reflect available data and therefore do not always reflect the total population defined in the ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy</title>
          <description>- Incidence of Medical Termination of Pregnancy</description>
          <population>ITT population; numbers reported reflect available data and therefore do not always reflect the total population defined in the ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5956"/>
                <count group_id="O2" value="5946"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored continuously throughout the study (from enrollment through 6-weeks post delivery) and recorded every 2-weeks.</time_frame>
      <desc>SAEs were monitored for any event that: resulted in maternal or fetal death; was life-threatening; required hospitalization; resulted in persistent or significant disability; or any other serious or unexpected AE that the investigators felt should be reported. Specific AEs to be monitored included maternal death, upper GI bleeding, fetal anomaly, gastroschisis, post-partum hemorrhage, or antepartum hemorrhage. Other [Not Including Serious] AEs were not monitored/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intervention Arm</title>
          <description>Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Arm</title>
          <description>Identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5943"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="5936"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="832" subjects_at_risk="5943"/>
                <counts group_id="E2" subjects_affected="857" subjects_at_risk="5936"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="5943"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="5936"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension admission or medical visit before delivery</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="5943"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="5936"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital anomaly</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="5943"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="5936"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper gastrointestinal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5943"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5936"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever or infection</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="5943"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="5936"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Maternal death</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5943"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="5936"/>
              </event>
              <event>
                <sub_title>Fetal loss</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="5943"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="5936"/>
              </event>
              <event>
                <sub_title>Neonatal death up to 28 days</sub_title>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="5943"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="5936"/>
              </event>
              <event>
                <sub_title>Miscarriage, abortion, or medical termination of pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="5943"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="5936"/>
              </event>
              <event>
                <sub_title>Preterm labour or preterm birth evaluation before delivery</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="5943"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="5936"/>
              </event>
              <event>
                <sub_title>Antepartum haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="5943"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="5936"/>
              </event>
              <event>
                <sub_title>Post-partum harmorrhage</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="5943"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="5936"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="5943"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="5936"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia or eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="5943"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="5936"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal spotting, bleeding, or leaking</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="5943"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="5936"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="-0" subjects_at_risk="-0"/>
                <counts group_id="E2" subjects_affected="-0" subjects_at_risk="-0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elizabeth McClure</name_or_title>
      <organization>RTI International</organization>
      <phone>919-316-3773</phone>
      <email>mcclure@rti.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

